Advancing glioblastoma imaging: Exploring the potential of organic fluorophore-based red emissive carbon dots

Over time, the interest in developing stable photosensitizers (PS) which both absorb and emit light in the red region (650 and 950 nm) has gained noticeable interest. Recently, carbon dots (CDs) have become the material of focus to act as a PS due to their high extinction coefficient, low cytotoxicity, and both high photo and thermal stability. In this work, a Federal and Drug Association (FDA) approved Near Infra-Red (NIR) organic fluorophore used for photo-imaging, indocyanine green (ICG), has been explored as a precursor to develop water-soluble red emissive CDs which possess red emission at 697 nm. Furthermore, our material was found to yield favorable red-imaging capabilities of glioblastoma stem-like cells (GSCs) meanwhile boasting low toxicity. Additionally with post modifications, our CDs have been found to have selectivity towards tumors over healthy tissue as well as crossing the blood-brain barrier (BBB) in zebrafish models

A comparative in vitro evaluation of two different magnetic devices detecting the stability of osseo-integrated implants

Geckili O, Bilhan H, Cilingir A, Mumcu E, Bural C. A comparative in vitro evaluation of two different magnetic devices detecting the stability of osseo-integrated implants. J Periodont Res 2012; 47: 508513. (c) 2012 John Wiley & Sons A/S Background and Objective: It is unknown whether the resonance frequency analysis (RFA) measurements made by two different magnetic resonance frequency analysers are comparable. This in vitro study was designed to compare the RFA measurements made by the two magnetic resonance frequency analysers and to evaluate the intra- and interobserver reliability of the magnetic devices. Material and Methods: Thirty-two implants were placed in four cow ribs. The RFA value of each implant was measured by five different examiners. The measurements were repeated five times, in both the buccal and mesial directions, for each implant at 2 h intervals, and the averages of registered implant stability quotient (ISQ) units were recorded as the buccal ISQ value and the mesial ISQ value for every implant. Results: No statistically significant differences (p > 0.05) were observed between the RFA measurements made by the two magnetic devices. The intra-observer reliability of both devices was excellent, whereas the interobserver reliability of the devices was poor. Conclusion: The results of the RFA measurements of both tested devices overlap. Although both devices show excellent intra-observer reliability, there are variations between the measurements of different examiners

Deletion of macro domain containing 2(MACRO D2) associated with transient hydrops fetalis

Cilingir, I. Uzun (Trakya Author) Sayin, Niyazi Cenk (Trakya Author) Gurkan, H.(Trakya Author) Ciftdemir, N. A. (Trakya Author) Atli, E. (Trakya Author) Inan, C. (Trakya Author) Erzincan, S. (Trakya Author) Sutcu, H. (Trakya Author) Vatansever, U. (Trakya Author) Varol, Fusun (Trakya Author)Macro Domain Containing 2 (MACRO D2) gene is a gene from macro family which is highly expressed in the ventriculer zone of the brain during embryonic development. Association between Autism spectrum disorders and MACRO D2 gene polymorphisms has been reported before [1] . Deletion in MACRO D2 gene has also been associated with Kabuki Syndrome which is a well described congential anomaly syndrome [2]

Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) -- OCT 25-28, 2017 -- Paris, FRANCEWOS: 000413730202068European Comm Treatment & Res Multiple Sclerosis, Americas Comm Treatment & Res Multiple SclerosisMerckMerck & Company; NovartisNovartis; Bayer-ScheringBayer AG; TevaMurat Terzi received travel grants from Merck, Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis